Table 1 Demographic and clinical characteristics of the study populations
Medicare | Commercial Insurance | |||||
|---|---|---|---|---|---|---|
Pre-TREAT a | Post-TREAT b | Post- FDA warning c | Pre-TREAT a | Post-TREAT b | Post- FDA warning c | |
No. unique patients | 48,614 | 64,694 | 117,452 | 103,980 | 127,054 | 244,191 |
No. patients in the median month of each period | 12,806 | 29,594 | 39,310 | 22,559 | 50,433 | 55,218 |
Male (%) | 52.1 | 49.8 | 49.4 | 55.2 | 55.6 | 56.3 |
Age 19–44 (%) | 0 | 0 | 0 | 13.3 | 12.1 | 11.4 |
Age 45–64 (%) | 1.2 | 1.0 | 1.2 | 85.6 | 85.1 | 84.9 |
Age > =65 (%) | 98.8 | 99.0 | 98.8 | 1.1 | 2.8 | 3.6 |
CKD stage 3 | 43.4 | 49.0 | 51.0 | 70.0 | 76.5 | 80.8 |
CKD stage 4 | 49.6 | 45.8 | 44.2 | 24.3 | 19.5 | 15.9 |
CKD stage 5 | 7.0 | 5.2 | 4.9 | 5.7 | 4 | 3.4 |
Diabetes mellitus (%) | 43.8 | 47.7 | 51.2 | 43.9 | 42.6 | 41.8 |
Hypertension (%) | 52.7 | 73.2 | 85.9 | 62.9 | 73.1 | 73.1 |
Heart Failure (%) | 10.1 | 17.4 | 21.2 | 5.2 | 6.2 | 6.4 |
Cerebrovascular disease (%) | 14.7 | 16.9 | 18.4 | 5.5 | 5.5 | 5.0 |
Peripheral Artery Disease (%) | 8.8 | 13.5 | 16.2 | 4.2 | 4.9 | 4.3 |
Chronic obstructive pulmonary disease (%) | 16.3 | 19.7 | 23.1 | 6.8 | 8.3 | 8.1 |
Nephrologist involvement (%) | 46.8 | 45.3 | 39.0 | 49.0 | 48.0 | 44.8 |
Charlson Comorbidity Index, mean (SD) | 4.2 (1.8) | 4.6 (2.0) | 4.9 (2.1) | 3.7 (1.8) | 3.7 (1.8) | 3.7 (1.8) |